If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 278
Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
Objective
Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
Protocol No
IIT-BEDI-CTDNA
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Objective
Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Protocol No
NRG-GY022
Categories
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patie
Objective
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Protocol No
BEIGENE-BGB-11417-105
A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B
Objective
Phase II MB-CART2019.1 for R/R DLBCL
Protocol No
MILTENYI-MB-CART2019-1-DLBCL
Categories
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA) Plus Stereotactic Re-Irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
Objective
SBRT +/- Pembrolizumab in Patients w/ Local-Regionally Recurrent or 2nd Primary Head and Neck Cancer
Protocol No
RTOG-3507
Categories
Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients with Localized Pancreatic Cancer
Objective
Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer
Protocol No
IIT-TSAI-PANC
Categories
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Objective
To compare the non-inferiority of bilateral salpingectomy (BLS) with delayed oophorectomy to bilateral salpingo-oophorectomy (BSO) to reduce the risk of ovarian cancer among women with deleterious BRCA1 germline mutations.
Protocol No
NRG-CC008
Categories
Evaluation of a Simple-Prep Controlled Embolic (GPX Trial)
Objective
Evaluation of a Simple-Prep Controlled Embolic (GPX)
Protocol No
VIR-FLUIDX-GPX
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Objective
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma?
We are doing this study to find out if this approach is better or worse than the usual approach to treating low tumor burden follicular lymphoma.
We are doing this study to find out if this approach is better or worse than the usual approach to treating low tumor burden follicular lymphoma.
Protocol No
SWOG-S2308
Categories
Feasibility of Assessing Physical Activity, Fatigue, and Inflammatory Biomarkers Among Chronic Myeloid Leukemia Patients with TKI-Induced Fatigue
Objective
MoveCML-DBS
Protocol No
IIT-MORELLI-MOVECML-DBS
Categories